Last edition
News about "Harvard Medical School"
Life Biosciences Doses First Patient in Phase 1 ER-100 Optic Neuropathy Trial
Life Biosciences has dosed the first patient in its phase 1 trial of ER-100, an investigational epigenetic restoration therapy for glaucoma and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION). The study marks a key milestone in evaluating a novel approach that targets the underlying causes of age-related vision loss.
Harvard Medical School | 09/06/2026 | By News Bureau | 857
National Institutes of Health Develops AI Tool to Predict Risk of Intimate Partner Violence
Researchers funded by National Institutes of Health have developed an AI-based clinical decision tool that predicts risk of Intimate Partner Violence using routine healthcare data with high accuracy.
Harvard Medical School | 17/03/2026 | By News Bureau | 112
Sun Pharma Launches UNLOXCYT for Advanced Cutaneous Squamous Cell Carcinoma
Sun Pharma has announced the US availability of UNLOXCYT for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not eligible for curative surgery or radiation. The updated label includes long-term data supporting durable efficacy and a favourable tolerability profile.
Harvard Medical School | 16/01/2026 | By News Bureau | 129
Sun Pharma Launches UNLOXCYT for Advanced Cutaneous Squamous Cell Carcinoma
Sun Pharma has announced the US availability of UNLOXCYT for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not eligible for curative surgery or radiation. The updated label includes long-term data supporting durable efficacy and a favourable tolerability profile.
Harvard Medical School | 16/01/2026 | By News Bureau | 129
US FDA Approves Label Update for Sun Pharma's UNLOXCYT
Sun Pharma has received US FDA approval for a label update to UNLOXCYT, the first and only PD-L1 inhibitor for advanced Cutaneous Squamous Cell Carcinoma (aCSCC), further supporting its clinical value with durable responses and a favourable safety profile for patients with multiple comorbidities.
Harvard Medical School | 27/11/2025 | By Dineshwori | 214
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy